Bicycle Therapeutics plc

BCYC

CIK 0001761612 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$887K
↓-91.1% -$9Mvs FY2025 (Q1)
Gross Profit
$887K
↓-91.1% -$9Mvs FY2025 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -27.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 11.98 (above 1.5 = solid)
  • Leverage
    96D/E 0.08 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.09x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -91.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -7382.4% · trend -2439.7pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$37M
non-cash dilution

Balance sheet · 2026-03-31

latest filed snapshot
Total assets
$652M
everything owned
Total liabilities
$98M
everything owed
Stockholders' equity
$554M
shareholder claim
Net debt
$-529M
Net cash position ($529M)

Recent performance · 34 quarters

Revenue↓-91.1% -$9M
$887K
Net Income↓-0.1% -$71K
$-61M
Free Cash Flow↑+23.4% +$20M
$-67M
Operating Margin↓-6678.8pts
-7382.4%

Drill down